bococizumab (PF-04950615)
B1481038
Phase 3 small_molecule terminated
Quick answer
bococizumab (PF-04950615) for Cardiovascular Disease is a Phase 3 program (small_molecule) at Pfizer with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer
- Indication
- Cardiovascular Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated